Phone : +91-22-2207 0099 Email : info@ottokemi.com, sales@ottokemi.com
2-[3-(1-Carboxy-5-{3-naphthalen-2-yl-2-[(4-{[2-(4,7,10-tris-carboxymethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetylamino]-methyl}-cyclohexanecarbonyl)-amino]-propionylamino}-pentyl)-ureido]-pentanedioic acid
PS 0072
puriss
C49H71N9O16.CF3COOH
38229090
5%
N/A
95%+
1042.14 (net)
Vail
DKFZ-PSMA-617 is an innovative and effective therapy for castrate-resistant metastatic prostate cancer patients.
DKFZ-PSMA-617 - a novel theranostic PSMA inhibitor for both diagnosis and endoradiotherapy of prostate cancer.
Cell biology, Cancer research
Powder
Colourless / white / off-white
1041.5
Safety Information for this product is unavailable at this time.
DisclaimerThe above particulars do not release the customer from the obligation to carry out an inspection of goods received. For laboratory use only. Not for drug, medical, household, or any other unauthorized application. We assume no liability for misuse or unauthorized application of the product. Please test before use.